MYC and B-cell non-Hodgkin lymphoma: Therefore, in Myc-driven malignancies or even high-grade B-cell lymphomas, especially in those with Myc rearrangement, such as double-hit or triple-hit lymphomas, Myc- and PD-L1-targeted combination therapy may be of potential therapeutic benefit.